Stock Price
8,727.00
Daily Change
-0.49%
Yearly
13.01%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 136.49 0.62 0.45% 21.67%
Alcon AG 71.36 -0.56 -0.78% 10.12%
Almirall SA 10.73 0.03 0.28% -11.47%
Amgen 231.84 -3.53 -1.50% -6.62%
argenx SE 251.20 -5.80 -2.26% 7.26%
Artemis Alpha 423.00 -10.00 -2.31% 5.22%
AstraZeneca 8,727.00 -43.00 -0.49% 13.01%
Bayer 52.06 -0.76 -1.44% -1.79%
Biogen 234.00 -5.30 -2.21% -14.55%
Bristol-Myers Squibb 64.51 -0.42 -0.65% -3.34%
Fresenius Medical Care 61.04 0.38 0.63% -10.71%
Fresenius 37.56 0.11 0.28% -3.03%
Genmab 2,296.00 -13.00 -0.56% -15.28%
Gilead Sciences 70.10 -1.67 -2.33% 4.52%
Galapagos 48.35 -1.02 -2.07% -44.84%
GRIFOLS 16.92 0.29 1.74% -33.74%
GlaxoSmithKline 1,701.20 -6.60 -0.39% 20.62%
Hikma Pharmaceutical 2,029.00 -40.00 -1.93% -18.71%
Eli Lilly 245.92 1.80 0.74% 23.90%
Lonza Group 647.00 -16.80 -2.53% 11.55%
H Lundbeck A/S 161.70 -0.55 -0.34% -30.42%
Merck 190.00 -3.85 -1.99% 27.65%
Merck & Co 81.72 0.34 0.42% -1.77%
Novartis 82.10 -0.35 -0.42% -4.00%
Orion 35.83 -0.01 -0.03% -8.76%
Pfizer 53.67 -1.28 -2.33% 46.12%
Philips 29.64 -0.01 -0.02% -34.04%
Recordati 52.22 -1.36 -2.54% 19.99%
Regeneron Pharmaceuticals 605.96 -9.28 -1.51% 13.50%
Roche Holding 364.90 -2.45 -0.67% 14.68%
Sanofi 92.06 -0.14 -0.15% 10.61%
UCB 88.82 -0.02 -0.02% 2.85%

Indexes Price Day Year
GB100 7559 -47.68 -0.63% 12.61%

AstraZeneca
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.